Chemkart India Ltd. · BSE:CHEMKART
Chemkart India — H1 FY27 Earnings Presentation
39 slides from Chemkart India's earnings presentation, Oct 30, 2026
Slide 1: Covering letter to BSE for investor presentation
CHEMKART INDIA LIMITED CIN-L51220MH2020PLC338631 403/404 K.L. Accolade, 4th Floor, Above Captain Gym, Nr. R.K. Hospital Santacruz (E), MUMBAI 400055 Email Id: [email protected] | Customer Care: +91 8828505052 Website: www.chemkart.com 30th October 2026 To The Corporate Relations Department BSE
Slide 2: Chemkart India Ltd Investor Presentation - October 2026
Chemkart India Ltd Investor Presentation - October 2026
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Chemkart India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Company Overview
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 5: The Foundation of Our Future
The Foundation of Our Future Mission Vision To drive growth and To be a global leader in excellence in food and end-to-end CDMO health ingredients solutions and trusted through quality sourcing, distribution of food, trusted partnerships, and health, and specialty innovative, sustainable ingredients
Slide 6: Company Snapshot
Company Snapshot 10+ Product Categories Certifications: ISO 9001:2015 | FSSAI | ETC | 150+ Ingredients Pan-India Distribution Network Revenue: 26.9% 500+ Trusted Clients (2 Year CAGR) EBITDA: 17.6% PAT: 19.6% 15% 30K Sq.Ft Warehouse (FY26) ROE: ROCE: 21% Investor Presentation – October 2026 5
Slide 7: About Chemkart
About Chemkart Chemkart India Limited, established in March 2015 and headquartered in Mumbai, is a B2B supplier of high-quality raw ingredients used in the manufacturing of nutritional, sports, and health supplements. The company serves a broad spectrum of manufacturers across India, offering a dive
Slide 8: Chemkart's Present Journey
Chemkart’s Present Journey 2023 2025 2022 • Launched Vinstar Biotech as Listed on the BSE SME Platform under the 2021 Expanded logistics a subsidiary to diversify and broaden business horizons. name Chemkart India 2020 Established EZRM as a footprint with new 30,000 sq. ft. • Established presence in
Slide 9: Vision 2030: Global Biotechnology Leader
Vision 2030: Global Biotechnology Leader 2030 2027 • Leadership as India’s #1 CRDMO in • Commissioning of EZRM SEZ 2029 Nutraceuticals & Personal Wellness Facility – India’s first nutraceutical- focused SEZ hub 2028 • Full-service CDMO offerings: • Global footprint with 60% manufacturing driven reve
Slide 10: Transitioning Into Manufacturing
Transitioning Into Manufacturing Chemkart India Limited (CIL) announced the commencement of full-scale construction of a greenfield facility at its wholly owned subsidiary, Easy Raw Materials Pvt. Ltd. (EZRM), located in the JNPT Special Economic Zone (SEZ), Maharashtra. This next-generation nutrace
Slide 11: Our upcoming facility JNPA
Our upcoming facility JNPA Projected Outlay for the Manufacturing Facility Investor Presentation – October 2026 10
Slide 12: Updates On Manufacturing Unit
Updates On Manufacturing Unit Easy Raw Materials Private Limited | F1 SEZ, JNPA Construction Progress Update RCC Structural Development Reinforcement and shuttering work for columns from the second slab to the third floor is in progress, alongside ongoing concrete curing activities. PEB Warehouse St
Slide 13: Showcasing Our Strength: Products & Partnerships
Showcasing Our Strength: Products & Partnerships Our Leading Product Portfolio Clientele at a Glance Glycine Creatine Monohydrate 200 Mesh Inositol BCAA 2:1:1 (Leucine, Isoleucine, Valine) L-Glutamine L-Carnitine N-Acetyl L-Cysteine (NAC) Taurine L-Glutathione (Reduced) Whey Protein Concentrate 80%
Slide 14: Domestic Stronghold with Emerging Global Reach
Domestic Stronghold with Emerging Global Reach Germany Slovakia Switzerland Turkey Portugal South Nepal Korea U.A.E Saudi Arabia Bhiwandi Geographic Revenue Breakup Sri Lanka 0.39% 99.61% New Zealand Export Domestic Warehousing facility in Bhiwandi, Maharashtra spans 28,259 sq. ft. across three floo
Slide 15: Robust Storage & Processing Capabilities
Robust Storage & Processing Capabilities 150+ Ingredients 30000 Sq.ft Warehouse 50+ 1.5MT/Day Blending Employee 1.8MT/Day Capacity Grinding Strength Capacity Investor Presentation – October 2026 14
Slide 16: Our Group Companies
Our Group Companies Vinstar Biotech Limited Easy Raw Materials Pvt. Ltd Supports science-led platforms in Focused on the manufacturing & biotech, life sciences, chemicals, and export of high-quality nutraceutical R&D-driven innovation. Its and wellness products, driven by involvement aligns with Che
Slide 17: Leadership Behind Chemkart
Leadership Behind Chemkart Ankit Shailesh Mehta Parul Shailesh Mehta Shailesh Vinodrai Mehta Chairman & Managing Director Promoter & Executive Director Promoter & Executive Director He holds a Bachelor's degree in With 9 years of experience in the A commerce graduate from the (Chemical Engineering)
Slide 18: Certifications
Certifications ISO 9001:2015 Certified FSSAI License ISO 22000:2018 Certified HALAL Certified KOSHER Certified Investor Presentation – October 2026 17
Slide 19: Industry Overview
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 20: India's Nutraceutical Market to Reach USD 85 Billion by 2033
India’s Nutraceutical Market to Reach USD 85 Billion by 2033 India’s nutraceutical market is growing at 10.3% CAGR, projected to reach USD 85 billion by 2033, backed by rising health-conscious consumer spending. A wellness-focused middle class and expanding elderly population are driving sustained d
Slide 21: Five Growth Drivers Shaping the Nutraceutical Industry
Five Growth Drivers Shaping the Nutraceutical Industry 01 Sports & Performance Nutrition 02 Protein Fortification & Diversification 03 Metabolic & Cognitive Wellness Rising participation in fitness Greater protein awareness Lifestyle-related health and organized sport is is widening the use of dairy
Slide 22: Strategic Overview
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 23: Present Edge & Future Focus
Present Edge & Future Focus: Strategic Advantages Path Ahead Experienced Team: Product Expansion: Strong leadership with deep industry knowledge. Our new manufacturing facility marks strategic entry into CDMO, expanding capabilities and offerings. Cost-Efficient Operations: Vertical Integration: Lea
Slide 24: Driving Growth Through Strategic Outreach
Driving Growth Through Strategic Outreach Strengthening customer relationships, global supplier partnerships and Strategic Customer Development technical capabilities to develop recurring business opportunities Strengthening strategic relationships with nutraceutical, sports nutrition, functional fo
Slide 25: Half-Yearly Financial Performance
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 26: Management Commentary
Management Commentary The first half of FY27 has been a landmark period for the Company, with an outstanding all-round performance delivered amid a global operating environment shaped by supply-chain shifts and pricing volatility across key product categories. In H1 FY27, consolidated revenue almost
Slide 27: Key Financial Highlights
Key Financial Highlights Revenue (INR Lacs) EBITDA (INR Lacs) PAT (INR Lacs) 99.4% 107.5% 122.2.% 20,587.3 2,937.0 2,255.9 10,322.6 1,415.6 1,015.2 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 EBITDA Margins (In %) PAT Margins (In %) 14.3% 11.0% 13.7% 9.8% H1 FY26 H1 FY27 H1 FY26 H1 FY27 Investor
Slide 28: Consolidated Income Statement
Consolidated Income Statement Particulars (Rs. Lacs) H1 FY27 H1 FY26 Y-o-Y H2 FY26 H-o-H Revenue from Operations 20,587.3 10,322.6 99.4% 11,160.4 84.5% Cost of Materials Consumed 111.3 1,005.2 141.1 Purchase of Stock in Trade 17,806.3 7,494.4 10,364.9 Changes in Inventories in Stock in Trade -904.2
Slide 29: Standalone Income Statement
Standalone Income Statement Particulars (Rs. Lacs) H1 FY27 H1 FY26 Y-o-Y H2 FY26 H-o-H Revenue from Operations 20,447.1 10,208.7 100.3% 11,050.8 85.0% Cost of Materials Consumed 111.3 1,005.2 141.1 Purchase of Stock in Trade 17,669.8 7,382.6 10,270.6 Changes in Inventories in Stock in Trade -845.8 -
Slide 30: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. Lacs) Sep-26 Mar-26 Equity And Liabilities (Rs. Lacs) Sep-26 Mar-26 Non ‐ Current Assets Shareholders Funds a)Property, plant and equipment and (a) Equity share capital 1,209.9 1,209.9 Intangible Assets (b)Reserves and Surplus 14,018.1 11,763.1 i)Property, plan
Slide 31: Standalone Balance Sheet
Standalone Balance Sheet Assets (Rs. Lacs) Sep-26 Mar-26 Equity And Liabilities (Rs. Lacs) Sep-26 Mar-26 Non ‐ Current Assets Shareholders Funds a)Property, plant and equipment and (a) Equity share capital 1,209.9 1,209.9 Intangible Assets (b)Reserves and Surplus 14,186.9 11,895.9 i)Property, plant
Slide 32: Consolidated Cashflow Statement
Consolidated Cashflow Statement Particulars (Rs. Lacs) Sep-26 Mar-26 Cash Flow from Operating Activities Profit before Tax 3,011.4 2,688.9 Adjustment for Non-Operating Items 17.9 224.9 Operating Profit before Working Capital Changes 3,029.3 2,913.8 Changes in Working Capital -4,555.6 -2,418.1 Cash G
Slide 33: Standalone Cashflow Statement
Standalone Cashflow Statement Particulars (Rs. Lacs) Sep-26 Mar-26 Cash Flow from Operating Activities Profit before Tax 3,071.0 2,800.6 Adjustment for Non-Operating Items -4.2 178.5 Operating Profit before Working Capital Changes 3,066.8 2,979.1 Changes in Working Capital -4,527.8 -2,602.9 Cash Gen
Slide 34: Historical Financial Performance
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 35: Segment-Wise Revenue Contribution
Segment-Wise Revenue Contribution FY25 FY26 H1 FY27 2.3% 2.7% 2.3% 1.8% 0.6% 2.1% 30.9% 28.8% 33.2% 44.4% 48.5% 50.0% 2.3% 11.4% 8.4% 11.9% 6.9% 3.0% 0.9% 2.0% 0.9% 1.6% 1.8% 1.5% Amino Acids Herbal Extract Health Supplement Nucleotide Protein Sports Nutrition Vitamin Other Product Category FY25 FY2
Slide 36: Key Financial Highlights
Key Financial Highlights Revenue (INR Lacs) EBITDA (INR Lacs) and EBITDA Margin (%) PAT (INR Lacs) and PAT Margin (%) 2,453.3 21,482.9 3,287.1 2,255.9 20,327.9 20,587.3 2,817.7 2,937.0 1,965.5 13,202.7 2,091.2 1,451.8 16.2% 12.1% 11.0% 15.8% 11.0% 9.1% 13.1% 14.3% FY24 FY25 FY26 H1 FY27 FY24 FY25 FY
Slide 37: Investment Rationale
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 38: Investment Rationale
Investment Rationale Profitable Product Mix Strong Customer Network Greenfield Expansion Specialty chemicals Focused on B2B, Investing in EZRM’s and nutraceuticals building trusted greenfield manufacturing across pharma, relationships to expand project to improve personal care, and B2B customers and
Slide 39: Thank You!
Company Chemkart India Limited CIN: L51220MH2020PLC338631 Email ID: [email protected] Tel: + 91 9136383828 Website: www.chemkart.com Thank You! Investor Relations Partner X-B4 Advisory LLP Rasika Sawant / Aagam Shah Tel: +91 95944 57518 / +91 8850166932 Email ID: [email protected] / [email protected]